Please assess the completion status of the following clinical trial:

Trial Title: Malaria Prevention Cambodia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Volunteer 18-65 years of age~2. Able to give informed consent~3. Likely to reside in malaria endemic area for the duration of the study~4. Available for follow-up for anticipated study duration, and agrees to participate for the duration of the study~5. Agrees not to seek outside medical care for febrile illness, except in emergency situations, unless referred by study team~6. Authorized by local commander to participate in the study if on active duty~Exclusion Criteria:~1. Known allergy or other contraindication to DHA, piperaquine treatment, and/or primaquine treatment~2. Significant acute comorbidity requiring urgent medical intervention~3. Positive malaria blood smear.~4. Treatment with an antimalarial drug in the past 30 days.~5. Pregnant or lactating female or a female of childbearing age who does not agree to use a highly effective method of birth control during the study~6. Significantly abnormal EKG including a QTcF interval greater than 450ms at baseline (or 470ms for females) using Fridericia's correction~7. Regular current use of known QTc prolonging medications~8. History of sudden cardiac death in an immediate family member, or personal history of known symptomatic coronary artery disease or arrhythmias~9. Judged by the investigator to be otherwise unsuitable for study participation or non-compliant with study requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- DHA-piperaquine (Type: EXPERIMENTAL): DHA-piperaquine monthly 2 day treatment course
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo control

Based on this trial design, predict the completion outcome and termination type (if applicable).